非诺贝特联合非洛地平缓释片对高血压合并血脂代谢紊乱患者的疗效及对HCY、PLR及hs-CRP的影响

Therapeutic efficacy of fenofibrate combined with felodipine sustained release tablets in patients with hypertension complicated with dyslipidemia and its impact on HCY,PLR and hs-CRP

目的探究与分析非诺贝特联合非洛地平缓释片对高血压合并血脂代谢紊乱患者的疗效及对同型半胱氨酸(HCY)、血小板淋巴细胞比值(PLR)及超敏C反应蛋白(hs-CRP)的影响。方法选取南京医科大学附属江苏盛泽医院2019年6月至2021年6月收治的高血压合并血脂代谢紊乱患者120例,采取随机数表法分为对照组与观察组,每组各60例,两组均给予调脂饮食干预,对照组给予非洛地平缓释片治疗,观察组在对照组基础上加用非诺贝特治疗,比较两组临床疗效、治疗前后血压、血脂、HCY、PLR及hs-CRP水平,同时观察两组治疗期间不良反应。结果观察组临床总有效率高于对照组,差异有统计学意义(P<0.05)。观察组治疗后收缩压(SBP)、舒张压(DBP)、收缩压变异性(SBPV)及舒张压变异性(DBPV)水平,三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)均低于对照组,高密度脂蛋白(HDL-C)高于对照组,HCY、PLR及hs-CRP水平低于对照组,差异有统计学意义(P<0.05)。两组治疗期间均未出现明显的不良反应。结论非诺贝特联合非洛地平缓释片对高血压合并血脂代谢紊乱患者有较好的临床疗效,改善血压以及血脂代谢紊乱水平,调节HCY、PLR及hs-CRP指标,且治疗期间未增加明显的不良反应,安全性有保障。

Objective To investigate and analyze the therapeutic efficacy of fenofibrate combined with felodipine sustained release tablets in patients with hypertension complicated with dyslipidemia and its impact on homocysteine(HCY),platelet lymphocyte ratio(PLR)and hypersensitive C reactive protein(hs-CRP).Methods A total of 120 patients with hypertension complicated with dyslipidemia admitted to and treated in Jiangsu Shengze Hospital Affiliated to Nanjing Medical University from June 2019 to June 2021 were selected,and they were divided into the control group(n=60)and the observation group(n=60)according to the random number table method.Both groups were treated with lipid-regulating diet intervention.The control group was treated with felodipine sustained release tablets,while the observation group was treated with fenofibrate on the basis of the control group.The clinical efficacy and the blood pressure,blood lipid,HCY,PLR and hs-CRP levels before and after treatment were compared between the two groups.At the same time,observe the adverse reactions of the two groups during the treatment.Results The clinical overall response rate of the observation group was higher than that of the control group,with statistically significant difference(P<0.05).After treatment,the levels of systolic blood pressure(SBP),diastolic blood pressure(DBP),systolic blood pressure variability(SBPV)and diastolic blood pressure variability(DBPV),the levels of triglycerides(TG),total cholesterol(TC),low density lipoprotein(LDL-C)in the observation group were all lower than those of the control group,the level of high density lipoprotein(HDL-C)in the observation group was higher than that of the control group,and the levels of HCY,PLR and hs-CRP in the observation group were all lower than those of the control group,with statistically significant differences(P<0.05).There was no obvious adverse reaction in the two groups during treatment.Conclusion Fenofibrate combined with felodipine sustained release tablets can obtain a better clinical efficacy in patients with hypertension complicated with dyslipidemia.It promotes the alleviation of blood pressure and dyslipidemia level,and regulates HCY,PLR and hs-CRP indices,and there is no obvious adverse reaction during treatment.Therefore,its safety is guaranteed.